Nothing Special   »   [go: up one dir, main page]

MX2019010539A - Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak. - Google Patents

Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak.

Info

Publication number
MX2019010539A
MX2019010539A MX2019010539A MX2019010539A MX2019010539A MX 2019010539 A MX2019010539 A MX 2019010539A MX 2019010539 A MX2019010539 A MX 2019010539A MX 2019010539 A MX2019010539 A MX 2019010539A MX 2019010539 A MX2019010539 A MX 2019010539A
Authority
MX
Mexico
Prior art keywords
membered heterocyclic
compounds
heterocyclic amide
jak inhibitors
inhibitors containing
Prior art date
Application number
MX2019010539A
Other languages
English (en)
Inventor
Smith Cameron
d e sullivan Steven
Jean Van Orden Lori
R Fatheree Paul
E L Brandt Gary
A Kleinschek Melanie
D Crater Glenn
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2019010539A publication Critical patent/MX2019010539A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos de fórmula (I): (ver fórmula I) que contienen una amida heterocíclica de 4 miembros, donde las variables se definen en la memoria descriptiva, o una sal farmacéuticamente aceptable de los mismos, que son útiles como inhibidores de quinasa JAK. La invención también provee composiciones farmacéuticas que comprenden tales compuestos, métodos para usar tales compuestos para tratar enfermedades respiratorias, y procesos e intermediarios útiles para preparar tales compuestos.
MX2019010539A 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak. MX2019010539A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469073P 2017-03-09 2017-03-09
PCT/US2018/021489 WO2018165392A1 (en) 2017-03-09 2018-03-08 Jak inhibitors containing a 4-membered heterocyclic amide

Publications (1)

Publication Number Publication Date
MX2019010539A true MX2019010539A (es) 2019-10-21

Family

ID=61683956

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010541A MX2019010541A (es) 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
MX2019010539A MX2019010539A (es) 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019010541A MX2019010541A (es) 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada como inhibidores de jak.

Country Status (20)

Country Link
US (10) US10208040B2 (es)
EP (2) EP3592742B1 (es)
JP (2) JP6974487B2 (es)
KR (2) KR102526764B1 (es)
CN (2) CN110461839B (es)
AR (2) AR111241A1 (es)
AU (2) AU2018231035B2 (es)
BR (2) BR112019018648A2 (es)
CA (1) CA2997772A1 (es)
DK (1) DK3592742T3 (es)
EA (2) EA037748B1 (es)
ES (1) ES2882186T3 (es)
IL (2) IL268689B2 (es)
MX (2) MX2019010541A (es)
PH (2) PH12019501941A1 (es)
PT (1) PT3592742T (es)
SG (2) SG11201907544VA (es)
TW (2) TWI754019B (es)
WO (2) WO2018165392A1 (es)
ZA (2) ZA201905585B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ741737A (en) 2015-11-03 2023-11-24 Theravance Biopharma R&D Ip Llc Jak kinase inhibitor compounds for treatment of respiratory disease
ES2840650T3 (es) * 2015-11-03 2021-07-07 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
SG11201907544VA (en) 2017-03-09 2019-09-27 Theravance Biopharma R&D Ip Llc Jak inhibitors containing a 4-membered heterocyclic amide
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
WO2018204233A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
AR116114A1 (es) * 2018-09-04 2021-03-31 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
MX2021002273A (es) 2018-09-04 2021-05-27 Theravance Biopharma R&D Ip Llc Proceso para preparar inhibidores de las jak y productos intermedios de estos.
BR112021004052A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas de dimetil-amino azetidina como inibidores de jak
US10968222B2 (en) * 2018-10-29 2021-04-06 Theravance Biopharma R&D Ip, Llc 2-azabicyclo hexane JAK inhibitor compound
PT3932919T (pt) * 2019-02-25 2024-07-30 Henan Medinno Pharmaceutical Tech Co Ltd Composto inibidor de jak e sua utilização
AU2020232757A1 (en) 2019-03-05 2021-10-07 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
WO2021108803A1 (en) * 2019-11-26 2021-06-03 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as jak inhibitors
WO2021136345A1 (zh) * 2019-12-30 2021-07-08 路良 Jak抑制剂化合物及其用途
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022178215A1 (en) * 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
CA3223194A1 (en) * 2021-06-25 2022-12-29 Theravance Biopharma R&D Ip, Llc Imidazolo indazole compounds as jak inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
US20120029190A1 (en) 2009-04-03 2012-02-02 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN104546846B (zh) 2009-12-21 2017-04-12 萨穆梅德有限公司 1H‑吡唑并[3,4‑b]吡啶及其治疗应用
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2654051T3 (es) 2013-12-05 2018-02-12 Pfizer Inc. Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
CN106459048A (zh) 2014-05-14 2017-02-22 辉瑞公司 吡唑并吡啶类和吡唑并嘧啶类
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
NZ741737A (en) 2015-11-03 2023-11-24 Theravance Biopharma R&D Ip Llc Jak kinase inhibitor compounds for treatment of respiratory disease
DK3712152T3 (da) 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
ES2840650T3 (es) 2015-11-03 2021-07-07 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
SG11201907544VA (en) 2017-03-09 2019-09-27 Theravance Biopharma R&D Ip Llc Jak inhibitors containing a 4-membered heterocyclic amide
SG11201909376TA (en) 2017-05-01 2019-11-28 Theravance Biopharma R&D Ip Llc Crystalline forms of a jak inhibitor compound
WO2018204233A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
AR116114A1 (es) 2018-09-04 2021-03-31 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
MX2021002273A (es) 2018-09-04 2021-05-27 Theravance Biopharma R&D Ip Llc Proceso para preparar inhibidores de las jak y productos intermedios de estos.
BR112021004052A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas de dimetil-amino azetidina como inibidores de jak

Also Published As

Publication number Publication date
AU2018231032A8 (en) 2019-10-17
JP6974487B2 (ja) 2021-12-01
EA201992126A1 (ru) 2020-02-05
CN110461839B (zh) 2022-08-23
TW201837037A (zh) 2018-10-16
IL268689B (en) 2022-10-01
US10519153B2 (en) 2019-12-31
AU2018231035B2 (en) 2021-09-09
TWI779016B (zh) 2022-10-01
EA037748B1 (ru) 2021-05-18
IL268689B2 (en) 2023-02-01
NZ756823A (en) 2021-04-30
US10392386B2 (en) 2019-08-27
ES2882186T3 (es) 2021-12-01
KR102526764B1 (ko) 2023-04-27
US20180258087A1 (en) 2018-09-13
JP2020510015A (ja) 2020-04-02
CN110382498A (zh) 2019-10-25
US20190119275A1 (en) 2019-04-25
SG11201907544VA (en) 2019-09-27
EA201992128A1 (ru) 2020-01-29
KR20190127796A (ko) 2019-11-13
US20190337945A1 (en) 2019-11-07
US20200216447A1 (en) 2020-07-09
JP2020510010A (ja) 2020-04-02
US10954237B2 (en) 2021-03-23
US20190127371A1 (en) 2019-05-02
AU2018231032A1 (en) 2019-09-05
US10550118B2 (en) 2020-02-04
IL268679B (en) 2021-10-31
US10196393B2 (en) 2019-02-05
AU2018231032B2 (en) 2021-08-19
DK3592742T3 (da) 2021-08-09
CA2997772A1 (en) 2018-09-09
US20230063643A1 (en) 2023-03-02
US11667637B2 (en) 2023-06-06
US20220289737A1 (en) 2022-09-15
AR111242A1 (es) 2019-06-19
US20200181141A1 (en) 2020-06-11
IL268689A (en) 2019-10-31
US10208040B2 (en) 2019-02-19
TW201840560A (zh) 2018-11-16
BR112019018648A2 (pt) 2020-06-16
SG11201907840RA (en) 2019-09-27
EA037261B1 (ru) 2021-03-01
PT3592742T (pt) 2021-07-30
EP3592742B1 (en) 2021-05-19
ZA201905618B (en) 2021-05-26
CN110461839A (zh) 2019-11-15
AR111241A1 (es) 2019-06-19
IL268679A (en) 2019-10-31
KR102533646B1 (ko) 2023-05-17
EP3592742A1 (en) 2020-01-15
TWI754019B (zh) 2022-02-01
US11453668B2 (en) 2022-09-27
US11878977B2 (en) 2024-01-23
EP3592743A1 (en) 2020-01-15
KR20190127798A (ko) 2019-11-13
PH12019501985A1 (en) 2020-10-05
AU2018231035A1 (en) 2019-09-05
US20210269436A1 (en) 2021-09-02
US11254669B2 (en) 2022-02-22
ZA201905585B (en) 2020-05-27
CN110382498B (zh) 2022-07-12
BR112019018649A2 (pt) 2020-04-07
MX2019010541A (es) 2019-10-21
WO2018165392A1 (en) 2018-09-13
PH12019501941A1 (en) 2020-07-06
WO2018165395A1 (en) 2018-09-13
US20180258088A1 (en) 2018-09-13
JP7134990B2 (ja) 2022-09-12

Similar Documents

Publication Publication Date Title
PH12019501941A1 (en) Jak inhibitors containing a 4-membered heterocyclic amide
PH12018500828A1 (en) Jak kinase inhibitor compounds for treatment of respiratory disease
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
MX2018013191A (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
MX2021002521A (es) Dimetilaminoazetidinaminas como inhibidores de jak.
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
PH12021550324A1 (en) 5 to 7 membered heterocyclic amides as jak inhibitors
PH12021551280A1 (en) Heteroaromatic compounds as vanin inhibitors
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2021006489A (es) Compuestos heteroaromaticos como inhibidores de vanina.
PH12019502693A1 (en) Heteroaromatic compounds as vanin inhibitors
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы